ROLE OF VITAMIN D IN ETIOPATHOGENESIS AND METABOLIC ABNORMALITIES SEEN IN POLYCYSTIC OVARIAN SYNDROME

  • SURANKITA SUKUL Department of Biochemistry, Burdwan Medical College, West Bengal, India.
  • JYOTIRMAYEE BAHINIPATI Department of Biochemistry, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.
  • ASHOK KUMAR DAS Department of Biochemistry, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.

Abstract

Objective: Polycystic ovarian syndrome (PCOS) is a common cause of ovarian dysfunction in women in reproductive age group. It is now the leading cause of infertility among premenopausal women. PCOS women usually suffer from metabolic disturbances and insulin resistance (IR). Vitamin D has shown a significant role in glucose and insulin metabolism. Correlation studies have been done to examine the role of vitamin D in PCOS. However, still, Vitamin D status in PCOS remains varied.


This study is an attempt to find out the association of Vitamin D with etiopathogenesis and metabolic risk factors seen in PCOS.


Methods: Hundred subjects (50 PCOS and 50 age-matched normal control) were recruited for the study. Difference in biochemical parameters in PCOS women and normal group was measured, and association of Vitamin D with etiological and biochemical parameters in PCOS was seen.


Results: There was a significant (p<0.001) increase in body mass index, serum insulin, fasting blood sugar (FBS), serum cholesterol, triglyceride, and low-density lipoprotein in PCOS. IR was observed in PCOS cases (homeostatic model assessment for β-cell function and IR = 6.40±1.96) compared to the control group (2.43±0.53). Serum 25(OH) Vitamin D3 was significantly decreased in PCOS (9.04±2.60 ng/ml) compared to control group (20.06±3.28 ng/ml). Negative correlation of serum Vitamin D was found with FBS, serum insulin, IR, HI, and serum testosterone. Vitamin D with metabolic parameters also showed a statistically significant negative correlation.


Conclusion: Vitamin D deficiency may be a common comorbid manifestation of PCOS. Hence, Vitamin D supplementation may decrease the potential risk of morbidity and mortality associated with PCOS. However, further studies are needed which should include assessment of Vitamin D in women at various stages of PCOS to enhance the temporal order of Vitamin D deficiency in relation to PCOS.

Keywords: Polycystic ovarian syndrome, Vitamin D, Homeostatic model assessment for β-cell function and insulin resistance, Hirsutism index

References

1. Laiza MS, Aline DS, Claudia BC, Fernanda ST, Roberto PA, Cristina CS. Metformin usage to induce ovulation in women with polycystic ovary syndrome: A meta-analysis. Int J Pharm Pharm Sci 2016;8:86-9.
2. Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: Overview and approaches for treatment. Diabetes Spectrum 2015;28:116-20.
3. Barthelmess EK, Naz RK. Polycystic ovary syndrome: Current status and future perspective. Front Biosci (Elite Ed) 2014;6:104-19.
4. Choudhary A, Jain S, Choudhari P. Prevalence and symptomatology of polycystic ovarian syndrome in Indian women: Is there a rising incidence? Int J Reprod Contracept Obstet Gynaecol 2017;6;4971-5.
5. Aghadavod E, Mollaei H, Nouri M, Hamishehkar H. Evaluation of relationship between body mass index with Vitamin D receptor gene expression and vitamin D levels of follicular fluid in overweight patients with polycystic ovary syndrome. Int J Fertil Steril 2017;11:105-11.
6. Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth. Int J Reprod Med 2014;2014:719050.
7. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev 2012;33:981-1030.
8. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
9. Beydoun HA, Stadtmauer L, Beydoun MA, Russell H, Zhao Y, Oehninger S, et al. Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies. Reprod Biomed Online 2009;18:856-63.
10. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: A systematic review and meta-analysis. Obes Rev 2013;14:95-109.
11. Nehra J, Kaushal J, Singhal SR, Ghalaut VS. Comparision of myo-inositol versus metformin on anthropometric parameters in polycystic ovarian syndrome in women. Int J Pharm Pharm Sci 2017;9:144-8.
12. Bu Z, Kuok K, Meng J, Wang R, Xu B, Zhang H, et al. The relationship between polycystic ovary syndrome, glucose tolerance status and serum preptin level. Reprod Biol Endocrinol 2012;10:10.
13. Bennal A, Sudha K. Effect of PCOS on glucose metabolism. Natl J Physiol Pharm Pharmacol 2013;3:167-70.
14. Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, et al. The effect of Vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest 2010;33:234-8.
15. Wanderley MD, Pereira LC, Santos CB, Cunha VS, Neves MV. Association between insulin resistance and cardiovascular risk factors in polycystic ovary syndrome patients. Rev Bras Ginecol Obstet 2018;40:188-95.
16. Behboudi-Gandevani S, Tehrani FR, Dovom MR, Farahmand M, Khomami MB, Noroozzadeh M, et al. Insulin resistance in obesity and polycystic ovary syndrome: Systematic review and meta-analysis of observational studies. Gynecol Endocrinol 2016;32:343-53.
17. Pauli JM, Raja-Khan N, Wu X, Legro RS. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med 2011;28:1445-54.
18. Jayagopal V, Kilpatrik ES, Jennings PE, Hepburn DA, Atkin SL. Biological variation of testosterone and sex hormone binding globulin as surrogate marker of insulin resistance. J Endocrinol Metab 2003;88:1528-33.
19. González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336-40.
20. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010;122:42-52.
21. Banaszewska B, Spaczy?ski RZ, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo and hyperinsulinemia. Rocz Akad Med Bialymst 2003;48:131-4.
22. Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA.Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi Med J 2007;28:1039-43.
23. Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL. The LH/ FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem 2006;43:217-9.
24. Yarak S, Bagatin E, Hassm MK, Parada MO, Filu ST. Hyperandrogenism and skin, polycystic ovary syndrome and peripheral insulin resistance. An Bras Dermatol 2005;80:395-410.
25. Shoaib OM, Mustafa SM, Nouren IH. Serum lipid profile in polycystic ovarian syndrome in Sudanese women. Int J Med Sci Public Health 2015;4:1605-10.
26. Rocha MP, Marcondes JA, Barcellos CR, Hayashida SA, Curi DD, da Fonseca ÂM, et al. Dyslipidemia in women with polycystic ovary syndrome: Incidence, pattern and predictors. Gynecol Endocrinol 2011;27:814-9.
27. Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: A pilot study. J Endocrinol Invest 2011;34:757-63.
28. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011;60:1475-81.
29. Kim JJ, Choi YM, Chae SJ, Hwang KR, Yoon SH, Kim MJ, et al. Vitamin D deficiency in women with polycystic ovary syndrome. Clin Exp Reprod Med 2014;41:80-5.
30. Rahimi-Ardabili H, Pourghassem Gargari B, Farzadi L. Effects of Vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. J Endocrinol Invest 2013;36:28-32.
31. Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J. The dependency of Vitamin D status on body mass index, gender, age and season. Anticancer Res 2009;29:3713-20.
32. Cebeci F, Onsun N, Mert M. Insulin resistance in women with hirsutism. Arch Med Sci 2012;8:342-6.
33. Vanlint S. Vitamin D and obesity. Nutrients 2013;5:949-56.
34. Panidis D, Balaris C, Farmakiotis D, Rousso D, Kourtis A, Balaris V, et al. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 2005;51:1691-7.
35. Zhang J, Ye J, Guo G, Lan Z, Li X, Pan Z, et al. Vitamin D status is negatively correlated with insulin resistance in Chinese Type 2 diabetes. Int J Endocrinol 2016;2016:1794894.
36. Kumar A, Barki S, Raghav V, Chaturvedi A, Kumar KV. Correlation of Vitamin D with metabolic parameters in polycystic ovarian syndrome. J Family Med Prim Care 2017;6:115-9.
37. Clemente-Postigo M, Muñoz-Garach A, Serrano M, Garrido-Sánchez L, Bernal-López MR, Fernández-García D, et al. Serum 25-hydroxy Vitamin D and adipose tissue Vitamin D receptor gene expression: Relationship with obesity and Type 2 diabetes. J Clin Endocrinol Metab 2015;100:E591-5.
38. Glintborg D, Andersen M. Management of endocrine disease: Morbidity in polycystic ovary syndrome. Eur J Endocrinol 2017;176:R53-R65.
39. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low serum 25-hydroxy Vitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006;114:577-83.
40. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009;161:575-82.
41. Zittermann A, Frisch S, Berthold HK, Götting C, Kuhn J, Kleesiek K, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009;89:1321-7.
42. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-11.
43. Firouzabadi RD, Aflatoonian A, Modarresi S, Sekhavat L, Taheri SM. Therapeutic effects of calcium and Vitamin D supplementation in women with PCOS. Complement Ther Clin Pract 2012;18:85-8.
44. Rashidi B, Haghollahi F, Shariat M, Zayerii F. The effects of calcium- Vitamin D and metformin on polycystic ovary syndrome: A pilot study. Taiwan J Obstet Gynecol 2009;48:142-7.
Statistics
78 Views | 14 Downloads
How to Cite
SURANKITA SUKUL, JYOTIRMAYEE BAHINIPATI, and ASHOK KUMAR DAS. “ROLE OF VITAMIN D IN ETIOPATHOGENESIS AND METABOLIC ABNORMALITIES SEEN IN POLYCYSTIC OVARIAN SYNDROME”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 9, July 2019, pp. 215-9, https://innovareacademics.in/journals/index.php/ajpcr/article/view/33310.
Section
Original Article(s)